Home Blog of Signal Transduction Cell Cycle Myc

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

Myc

Identification of novel inhibitors for trigger factor (TF) of M. tb: an in silico investigation

419 views | Oct 29 2023

A computational model of the Mycobacterium tuberculosis trigger factor protein was developed and two potential inhibitors, HTS02984 and S06856, were identified through virtual screening, offering potential avenues for the development of tuberculosis therapies. [Read the Full Post]

Tryptophan metabolism induced by TDO2 promotes prostatic cancer chemotherapy resistance in a AhR/c-Myc dependent manner

771 views | Oct 25 2023

Elevated expression of tryptophan 2,3-dioxygenase 2 (TDO2) promotes tryptophan metabolism and kynurenine production, activating the AhR/c-Myc/ABC-SLC transporters signaling pathway and contributing to chemoresistance in prostatic cancer. [Read the Full Post]

Improved antitumor activity against prostate cancer via synergistic targeting of Myc and GFAT-1

415 views | Oct 19 2023

Simultaneous targeting of Myc and GFAT-1 using inhibitors and a nanocarrier delivery system shows promise as a novel strategy for the treatment of prostate cancer. [Read the Full Post]

Acetylation regulates the nucleocytoplasmic distribution and oncogenic function of karyopherin alpha 2 in lung adenocarcinoma

684 views | Sep 18 2023

The acetylation of KPNA2 by CBP/p300 promotes cytosolic localization and suppresses its oncogenic activity in lung cancer cells. [Read the Full Post]

Degradation of MYC by the mutant p53 reactivator drug, COTI-2 in breast cancer cells

496 views | Sep 08 2023

The study demonstrated that the mutant p53 reactivating drug COTI-2 effectively degraded MYC protein and showed synergistic growth inhibition when combined with an MYC inhibitor, suggesting its potential as a broad-spectrum anticancer therapy. [Read the Full Post]

RUNX1 isoform disequilibrium promotes the development of trisomy 21-associated myeloid leukemia

429 views | Sep 07 2023

The study proposes that an imbalance of RUNX1 isoforms, particularly elevated expression of RUNX1A, in combination with the Gata1s mutation, contributes to the development of myeloid leukemia associated with Down syndrome (ML-DS), and restoring the equilibrium between RUNX1A and RUNX1C holds potential for targeted therapies. [Read the Full Post]

The BET PROTAC inhibitor dBET6 protects against retinal degeneration and inhibits the cGAS-STING in response to light damage

467 views | Aug 25 2023

The study demonstrates that targeted degradation of BET proteins using dBET6 effectively inhibits the cGAS-STING pathway in reactive retinal macrophages/microglia, providing neuroprotective effects and suggesting a potential therapeutic approach for retinal degenerative diseases. [Read the Full Post]

Long non-coding RNA HIF1A-As2 and MYC form a double-positive feedback loop to promote cell proliferation and metastasis in KRAS-driven non-small cell lung cancer

562 views | May 25 2023

This passage describes a study on the role of lncRNA HIF1A-As2 in regulating the activation of KRAS in lung cancer and its potential as a therapeutic target. [Read the Full Post]

Construction of m6A-Related lncRNA Prognostic Signature Model and Immunomodulatory Effect in Glioblastoma Multiforme

582 views | Jul 22 2022

Pan Xie et al. constructed an m6A-associated lncRNA risk model to predict the prognosis of GBM patients and provided new ideas for the treatment of GBM. [Read the Full Post]

Tumorigenic circulating tumor cells from xenograft mouse models of non-metastatic NSCLC patients reveal distinct single cell heterogeneity and drug responses

696 views | Mar 15 2022

Kanve N Suvilesh et al. showed that CDX models deserved further development and studied to discover personalized strategies against micrometastases in non-metastatic NSCLC patients. [Read the Full Post]